Banner Blood Marrow Transplant Program and City of Hope Banner, Phoenix, Arizona, USA.
Biol Blood Marrow Transplant. 2010 Aug;16(8):1099-106. doi: 10.1016/j.bbmt.2010.02.013. Epub 2010 Feb 19.
Failure to engraft donor cells is a devastating complication after allogeneic hematopoietic cell transplantation (HCT). We describe the results of 122 patients reported to the National Marrow Donor Program between 1990 and 2005, who received a second unrelated donor HCT after failing to achieve an absolute neutrophil count of >or=500/microL without recurrent disease. Patients were transplanted for leukemia (n = 83), myelodysplastic disorders (n = 16), severe aplastic anemia (n = 20), and other diseases (n = 3). The median age was 29 years. Twenty-four patients received second grafts from a different unrelated donor. Among 98 patients who received a second graft from the same donor, 28 received products that were previously collected and cryopreserved for the first transplantation. One-year overall survival (OS) after second transplant was 11%, with 10 patients alive at last follow-up. We observed no differences between patients who received grafts from the same or different donors, or in those who received fresh or cryopreserved product. The outcomes after a second allogeneic HCT for primary graft failure are dismal. Identifying risk factors for primary graft failure can decrease the incidence of this complication. Further studies are needed to test whether early recognition and hastened procurement of alternative grafts can improve transplant outcomes for primary graft failure.
植入供体细胞失败是异基因造血细胞移植(HCT)后一种严重的并发症。我们描述了 1990 年至 2005 年间向国家骨髓供者计划报告的 122 例患者的结果,这些患者在没有复发疾病的情况下,未能达到绝对中性粒细胞计数>或=500/μL,接受了第二次无关供体 HCT。患者接受移植的疾病包括白血病(n=83)、骨髓增生异常综合征(n=16)、严重再生障碍性贫血(n=20)和其他疾病(n=3)。中位年龄为 29 岁。24 例患者接受了来自不同无关供体的第二次移植物。在 98 例从同一供体接受第二次移植物的患者中,28 例接受了之前为第一次移植而收集和冷冻保存的产品。第二次移植后 1 年总生存率(OS)为 11%,最后一次随访时有 10 例患者存活。我们观察到从同一供体或不同供体接受移植物的患者、接受新鲜或冷冻保存产品的患者之间没有差异。原发性移植物失败后进行第二次同种异体 HCT 的结果是悲惨的。确定原发性移植物失败的风险因素可以降低这种并发症的发生率。需要进一步的研究来测试是否早期识别和加速获得替代移植物可以改善原发性移植物失败的移植结果。